How to Buy aartidrugs Shares on Fincept?
You can buy Aarti Drugs Limited shares on Different Brokers & Banks by creating an account and completing KYC verification online.
NSE: Aarti Drugs Limited Share Price Today, Share Analysis, Latest Updates & Insights | Fincept
Stay informed with the latest announcements for Aartidrugs, including updates on board meetings and corporate actions.
Aarti Drugs Limited - https://www.aartidrugs.co.in
Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, moxifloxacin, norfloxacin, ofloxacin, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzene sulphonyl chloride, benzene sulphonic acid, benzene sulphonic acid methyl ester, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, para chlorobenznesulfonamide, para toluenesulfonyl hydrazide, para toluenesulfonamide, and sodium benzenesulfonate. In addition, it offers pharma intermediate products, which includes Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Tinidazole, and Zolpidem. Further, the company develops drugs for the antioxidant, antifungal, cardiovascular, and antidiabetic therapeutic areas. The company was incorporated in 1984 and is headquartered in Mumbai, India.
Aarti Drugs Limited Share Price Today
399.00
OPEN
415.45
HIGH
387.00
LOW
407.95
CLOSE
251 K
VOLUME
3,863 Cr
Market Cap
128382
Average Volume
Healthcare
Sector
NSI
Exchange
Aarti Drugs Limited Share Analysis & 2025 Insights
Investor Presentations
| Date | Description | Download |
|---|
SIP
Lumpsum
Invested Amount: ₹
Estimated Returns: ₹
Total Value: ₹
NSE: AARTIDRUGS Stock Actions
Company |
Symbol |
ISIN |
Subject |
Ex Date |
Face Value |
Broadcast Date |
|---|---|---|---|---|---|---|
Aarti Drugs Limited |
AARTIDRUGS |
INE767A01016 |
Buy Back |
05 Sep 2024 |
10 |
N/A |
Aarti Drugs Limited |
AARTIDRUGS |
INE767A01016 |
Interim Dividend - Re 1 Per Share |
06 Feb 2024 |
10 |
N/A |
Aarti Drugs Limited |
AARTIDRUGS |
INE767A01016 |
Buy Back |
04 Aug 2023 |
10 |
N/A |
Aarti Drugs Limited |
AARTIDRUGS |
INE767A01016 |
Interim Dividend - Rs 1 Per Share |
08 Feb 2023 |
10 |
N/A |
Aarti Drugs Limited |
AARTIDRUGS |
INE767A01016 |
Interim Dividend - Re 1 Per Share |
09 Feb 2022 |
10 |
N/A |
NSE: AARTIDRUGS Recent Announcements
Symbol |
Date |
Description |
Industry |
|---|---|---|---|
AARTIDRUGS |
27 Dec 2024, 18:29:18 |
Trading Window-XBRL |
Pharmaceuticals |
AARTIDRUGS |
27 Dec 2024, 18:27:48 |
Trading Window |
Pharmaceuticals |
AARTIDRUGS |
24 Dec 2024, 15:08:39 |
Action(s) taken or orders passed |
Pharmaceuticals |
AARTIDRUGS |
15 Dec 2024, 22:00:11 |
Loss/Duplicate-Share Certificate-XBRL |
Pharmaceuticals |
AARTIDRUGS |
15 Dec 2024, 21:56:41 |
Loss of Share Certificates |
Pharmaceuticals |
NSE: AARTIDRUGS Corporate Governance
Name |
Symbol |
Timestamp |
Submission Date |
XBRL Document |
|---|---|---|---|---|
Aarti Drugs Limited |
AARTIDRUGS |
15 Oct 2024, 20:34:00 |
15 Oct 2024, 20:34:00 |
|
Aarti Drugs Limited |
AARTIDRUGS |
09 Jul 2024, 19:21:00 |
09 Jul 2024, 19:21:00 |
|
Aarti Drugs Limited |
AARTIDRUGS |
19 Apr 2024, 20:27:00 |
19 Apr 2024, 20:45:00 |
|
Aarti Drugs Limited |
AARTIDRUGS |
12 Jan 2024, 12:45:00 |
12 Jan 2024, 13:15:00 |
|
Aarti Drugs Limited |
AARTIDRUGS |
16 Oct 2023, 14:01:00 |
16 Oct 2023, 14:30:00 |
NSE: AARTIDRUGS Detailed Governance
Category |
Date of Birth |
Date of Initial Appointment |
DIN |
Director Name |
Status |
|---|---|---|---|---|---|
Chairperson & Executive Director-CEO-MD |
16 Aug 1947 |
05 Jan 1985 |
00005618 |
Prakash Moreshwar Patil |
Active |
Executive Director-MD |
03 Jun 1974 |
16 Aug 2012 |
00066291 |
Rashesh Chandrakant Gogri |
Active |
Executive Director-MD |
19 Nov 1962 |
02 Jan 1987 |
00005340 |
Harshit Manilal Savla |
Active |
Executive Director |
12 Oct 1963 |
15 Sep 1995 |
00005501 |
Harit Pragji Shah |
Active |
Executive Director |
03 Jun 1963 |
18 Oct 2000 |
01186406 |
Uday Moreshwar Patil |
Active |
NSE: AARTIDRUGS Board Meetings
Purpose |
Symbol |
Industry |
ISIN |
Name |
Time |
|---|---|---|---|---|---|
AARTI DRUGS LIMITED has informed the Exchange about Board Meeting to be held on 24-Oct-2024 to inter-alia consider and approve the Audited Financial results of the Company for the Quarterly ended September 2024 . |
AARTIDRUGS |
N/A |
INE767A01016 |
Aarti Drugs Limited |
17 Oct 2024, 19:16:32 |
AARTI DRUGS LIMITED has informed the Exchange about Board Meeting to be held on 26-Aug-2024 to consider Buyback. |
AARTIDRUGS |
N/A |
INE767A01016 |
Aarti Drugs Limited |
27 Aug 2024, 21:26:04 |
Financial Results |
AARTIDRUGS |
N/A |
INE767A01016 |
Aarti Drugs Limited |
19 Jul 2024, 14:01:27 |
Financial Results |
AARTIDRUGS |
N/A |
INE767A01016 |
Aarti Drugs Limited |
26 Apr 2024, 20:21:02 |
Financial Results/Dividend |
AARTIDRUGS |
N/A |
INE767A01016 |
Aarti Drugs Limited |
17 Jan 2024, 18:59:02 |
NSE: AARTIDRUGS Event Calendar
Purpose |
Symbol |
Industry |
ISIN |
Name |
Time |
Description |
|---|---|---|---|---|---|---|
Financial Results |
AARTIDRUGS |
- |
INE767A01016 |
Aarti Drugs Limited |
17 Oct 2024, 00:00:00 |
To consider and approve the financial results for the period ended September 30, 2024 |
Buyback |
AARTIDRUGS |
- |
INE767A01016 |
Aarti Drugs Limited |
21 Aug 2024, 00:00:00 |
To consider buyback for equity shares |
Financial Results |
AARTIDRUGS |
- |
INE767A01016 |
Aarti Drugs Limited |
19 Jul 2024, 00:00:00 |
To consider and approve the financial results for the period ended Jun 30, 2024 |
Financial Results |
AARTIDRUGS |
- |
INE767A01016 |
Aarti Drugs Limited |
26 Apr 2024, 00:00:00 |
To consider and approve the financial results for the period ended March 31, 2024 |
Financial Results/Dividend |
AARTIDRUGS |
- |
INE767A01016 |
Aarti Drugs Limited |
17 Jan 2024, 00:00:00 |
To consider and approve the financial results for the period ended December 31, 2023 and Interim dividend for the FY 2023-24, if any |
NSE: AARTIDRUGS Balance Sheet Data In (Cr)
| date | period_type | Treasury Shares Number | Ordinary Shares Number | Share Issued | Net Debt | Total Debt | Tangible Book Value | Invested Capital | Working Capital | Net Tangible Assets | Capital Lease Obligations | Common Stock Equity | Total Capitalization | Total Equity Gross Minority Interest | Minority Interest | Stockholders Equity | Other Equity Interest | Retained Earnings | Additional Paid In Capital | Capital Stock | Common Stock | Total Liabilities Net Minority Interest | Total Non Current Liabilities Net Minority Interest | Other Non Current Liabilities | Non Current Pension And Other Postretirement Benefit Plans | Tradeand Other Payables Non Current | Non Current Deferred Revenue | Non Current Deferred Taxes Liabilities | Long Term Debt And Capital Lease Obligation | Long Term Capital Lease Obligation | Long Term Debt | Long Term Provisions | Current Liabilities | Other Current Liabilities | Current Debt And Capital Lease Obligation | Current Capital Lease Obligation | Current Debt | Pensionand Other Post Retirement Benefit Plans Current | Current Provisions | Payables | Other Payable | Dividends Payable | Total Tax Payable | Accounts Payable | Total Assets | Total Non Current Assets | Other Non Current Assets | Non Current Prepaid Assets | Investmentin Financial Assets | Available For Sale Securities | Goodwill And Other Intangible Assets | Other Intangible Assets | Net PPE | Accumulated Depreciation | Gross PPE | Construction In Progress | Other Properties | Machinery Furniture Equipment | Buildings And Improvements | Land And Improvements | Properties | Current Assets | Other Current Assets | Restricted Cash | Prepaid Assets | Inventory | Other Inventories | Finished Goods | Work In Process | Raw Materials | Other Receivables | Taxes Receivable | Accounts Receivable | Allowance For Doubtful Accounts Receivable | Gross Accounts Receivable | Cash Cash Equivalents And Short Term Investments | Other Short Term Investments | Cash And Cash Equivalents | Cash Equivalents | Cash Financial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30T00:00:00 | quarterly | 0.00 | 91,270,000.00 | 91,270,000.00 | 5,767,700,000.00 | 5,901,000,000.00 | 12,751,600,000.00 | 18,655,100,000.00 | 4,747,700,000.00 | 12,751,600,000.00 | 19,900,000.00 | 12,774,000,000.00 | 15,655,400,000.00 | 12,777,890,000.00 | 3,890,000.00 | 12,774,000,000.00 | 11,861,300,000.00 | 0.00 | 0.00 | 912,700,000.00 | 912,700,000.00 | 11,517,610,000.00 | 3,706,510,000.00 | 10,000.00 | 0.00 | 0.00 | 0.00 | 785,200,000.00 | 2,892,200,000.00 | 10,800,000.00 | 2,881,400,000.00 | 27,400,000.00 | 7,811,100,000.00 | 574,900,000.00 | 3,008,800,000.00 | 9,100,000.00 | 2,999,700,000.00 | 0.00 | 56,000,000.00 | 3,976,200,000.00 | 0.00 | 0.00 | 0.00 | 3,976,200,000.00 | 24,295,500,000.00 | 11,736,700,000.00 | 174,000,000.00 | 0.00 | 199,700,000.00 | 0.00 | 22,400,000.00 | 0.00 | 11,340,600,000.00 | 0.00 | 11,340,600,000.00 | 2,986,900,000.00 | 8,353,700,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12,558,800,000.00 | 715,500,000.00 | 0.00 | 0.00 | 4,700,000,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2,600,000.00 | 19,600,000.00 | 6,825,500,000.00 | 0.00 | 0.00 | 295,600,000.00 | 182,200,000.00 | 113,400,000.00 | 0.00 | 0.00 |
| 2024-03-31T00:00:00 | quarterly | 0.00 | 91,935,000.00 | 91,935,000.00 | 5,556,737,000.00 | 5,642,800,000.00 | 12,447,295,000.00 | 18,439,649,000.00 | 5,251,772,000.00 | 12,447,295,000.00 | 18,636,000.00 | 12,815,485,000.00 | 15,568,777,000.00 | 12,819,543,000.00 | 4,058,000.00 | 12,815,485,000.00 | 11,896,200,000.00 | 11,552,484,000.00 | 42,848,000.00 | 919,350,000.00 | 919,350,000.00 | 11,504,037,000.00 | 3,548,610,000.00 | -1,000.00 | 27,410,000.00 | 0.00 | 1,699,000.00 | 757,070,000.00 | 2,762,432,000.00 | 9,140,000.00 | 2,753,292,000.00 | 27,400,000.00 | 7,955,427,000.00 | 2,000.00 | 2,880,368,000.00 | 9,496,000.00 | 2,870,872,000.00 | 29,543,000.00 | 29,500,000.00 | 4,830,758,000.00 | 297,669,000.00 | 5,030,000.00 | 31,976,000.00 | 4,496,083,000.00 | 24,323,580,000.00 | 11,116,327,000.00 | 197,000,000.00 | 8,994,000.00 | 199,741,000.00 | 199,741,000.00 | 368,190,000.00 | 368,190,000.00 | 10,539,402,000.00 | -5,746,009,000.00 | 16,285,411,000.00 | 2,440,310,000.00 | 17,505,000.00 | 10,632,795,000.00 | 2,257,136,000.00 | 937,665,000.00 | 0.00 | 13,207,199,000.00 | 1,092,700,000.00 | 5,030,000.00 | 1,131,051,000.00 | 4,858,923,000.00 | 51,932,000.00 | 1,490,379,000.00 | 1,281,269,000.00 | 2,035,343,000.00 | 77,374,000.00 | 0.00 | 7,045,536,000.00 | -29,673,000.00 | 7,075,209,000.00 | 89,285,000.00 | 21,858,000.00 | 67,427,000.00 | 0.00 | 67,427,000.00 |
| 2024-03-31T00:00:00 | annual | 0.00 | 91,935,000.00 | 91,935,000.00 | 5,556,737,000.00 | 5,642,800,000.00 | 12,447,295,000.00 | 18,439,649,000.00 | 5,251,772,000.00 | 12,447,295,000.00 | 18,636,000.00 | 12,815,485,000.00 | 15,568,777,000.00 | 12,819,543,000.00 | 4,058,000.00 | 12,815,485,000.00 | 11,896,200,000.00 | 11,552,484,000.00 | 42,848,000.00 | 919,350,000.00 | 919,350,000.00 | 11,504,037,000.00 | 3,548,610,000.00 | -1,000.00 | 27,410,000.00 | 0.00 | 1,699,000.00 | 757,070,000.00 | 2,762,432,000.00 | 9,140,000.00 | 2,753,292,000.00 | 27,400,000.00 | 7,955,427,000.00 | 2,000.00 | 2,880,368,000.00 | 9,496,000.00 | 2,870,872,000.00 | 29,543,000.00 | 29,500,000.00 | 4,830,758,000.00 | 297,669,000.00 | 5,030,000.00 | 31,976,000.00 | 4,496,083,000.00 | 24,323,580,000.00 | 11,116,327,000.00 | 197,000,000.00 | 8,994,000.00 | 199,741,000.00 | 199,741,000.00 | 368,190,000.00 | 368,190,000.00 | 10,539,402,000.00 | -5,746,009,000.00 | 16,285,411,000.00 | 2,440,310,000.00 | 17,505,000.00 | 10,632,795,000.00 | 2,257,136,000.00 | 937,665,000.00 | 0.00 | 13,207,199,000.00 | 1,092,700,000.00 | 5,030,000.00 | 1,131,051,000.00 | 4,858,923,000.00 | 51,932,000.00 | 1,490,379,000.00 | 1,281,269,000.00 | 2,035,343,000.00 | 77,374,000.00 | 0.00 | 7,045,536,000.00 | -29,673,000.00 | 7,075,209,000.00 | 89,285,000.00 | 21,858,000.00 | 67,427,000.00 | 0.00 | 67,427,000.00 |
| 2023-09-30T00:00:00 | quarterly | 0.00 | 91,935,000.00 | 91,935,000.00 | 5,744,500,000.00 | 5,891,000,000.00 | 12,082,300,000.00 | 17,966,100,000.00 | 5,053,000,000.00 | 12,082,300,000.00 | 19,300,000.00 | 12,094,400,000.00 | 14,215,400,000.00 | 12,098,045,000.00 | 3,645,000.00 | 12,094,400,000.00 | 11,175,000,000.00 | 0.00 | 0.00 | 919,400,000.00 | 919,400,000.00 | 11,420,255,000.00 | 3,092,255,000.00 | -45,000.00 | 0.00 | 0.00 | 0.00 | 730,000,000.00 | 2,126,200,000.00 | 5,200,000.00 | 2,121,000,000.00 | 83,200,000.00 | 8,328,000,000.00 | 428,000,000.00 | 3,764,800,000.00 | 14,100,000.00 | 3,750,700,000.00 | 0.00 | 48,700,000.00 | 4,086,500,000.00 | 0.00 | 0.00 | 0.00 | 4,086,500,000.00 | 23,518,300,000.00 | 10,137,300,000.00 | 211,000,000.00 | 0.00 | 185,100,000.00 | 0.00 | 12,100,000.00 | 0.00 | 9,729,100,000.00 | 0.00 | 9,729,100,000.00 | 3,047,300,000.00 | 6,681,800,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13,381,000,000.00 | 943,100,000.00 | 0.00 | 0.00 | 5,152,300,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7,035,700,000.00 | 0.00 | 0.00 | 249,900,000.00 | 122,700,000.00 | 127,200,000.00 | 0.00 | 0.00 |
| 2023-03-31T00:00:00 | quarterly | 0.00 | 92,600,000.00 | 92,600,000.00 | 5,990,158,000.00 | 6,089,145,000.00 | 11,681,056,000.00 | 17,989,539,000.00 | 5,423,111,000.00 | 11,681,056,000.00 | 23,953,000.00 | 11,924,347,000.00 | 13,971,120,000.00 | 11,926,680,000.00 | 2,333,000.00 | 11,924,347,000.00 | 10,998,300,000.00 | 10,205,349,000.00 | 36,198,000.00 | 926,000,000.00 | 926,000,000.00 | 12,287,302,000.00 | 2,792,531,000.00 | -33,000.00 | 30,347,000.00 | 122,661,000.00 | 1,699,000.00 | 709,681,000.00 | 2,050,804,000.00 | 4,031,000.00 | 2,046,773,000.00 | 72,677,000.00 | 9,494,771,000.00 | 445,200,000.00 | 4,038,341,000.00 | 19,922,000.00 | 4,018,419,000.00 | 43,673,000.00 | 43,700,000.00 | 5,298,353,000.00 | 294,017,000.00 | 5,769,000.00 | 73,246,000.00 | 4,925,321,000.00 | 24,213,982,000.00 | 9,296,048,000.00 | 236,700,000.00 | 5,607,000.00 | 187,992,000.00 | 187,992,000.00 | 243,291,000.00 | 243,291,000.00 | 8,859,158,000.00 | -5,259,565,000.00 | 14,118,723,000.00 | 2,104,830,000.00 | 21,864,000.00 | 9,121,916,000.00 | 1,932,448,000.00 | 937,665,000.00 | 0.00 | 14,917,882,000.00 | 900,500,000.00 | 5,769,000.00 | 951,266,000.00 | 5,162,910,000.00 | 47,807,000.00 | 1,265,324,000.00 | 1,728,174,000.00 | 2,121,605,000.00 | 65,716,000.00 | 0.00 | 8,648,392,000.00 | -39,562,000.00 | 8,687,954,000.00 | 83,829,000.00 | 8,795,000.00 | 75,034,000.00 | 8,795,000.00 | 75,034,000.00 |
| 2023-03-31T00:00:00 | annual | 0.00 | 92,600,000.00 | 92,600,000.00 | 5,990,158,000.00 | 6,089,145,000.00 | 11,681,056,000.00 | 17,989,539,000.00 | 5,423,111,000.00 | 11,681,056,000.00 | 23,953,000.00 | 11,924,347,000.00 | 13,971,120,000.00 | 11,926,680,000.00 | 2,333,000.00 | 11,924,347,000.00 | 10,998,300,000.00 | 10,205,349,000.00 | 36,198,000.00 | 926,000,000.00 | 926,000,000.00 | 12,287,302,000.00 | 2,792,531,000.00 | -33,000.00 | 30,347,000.00 | 122,661,000.00 | 1,699,000.00 | 709,681,000.00 | 2,050,804,000.00 | 4,031,000.00 | 2,046,773,000.00 | 72,677,000.00 | 9,494,771,000.00 | 445,200,000.00 | 4,038,341,000.00 | 19,922,000.00 | 4,018,419,000.00 | 43,673,000.00 | 43,700,000.00 | 5,298,353,000.00 | 294,017,000.00 | 5,769,000.00 | 73,246,000.00 | 4,925,321,000.00 | 24,213,982,000.00 | 9,296,048,000.00 | 236,700,000.00 | 5,607,000.00 | 187,992,000.00 | 187,992,000.00 | 243,291,000.00 | 243,291,000.00 | 8,859,158,000.00 | -5,259,565,000.00 | 14,118,723,000.00 | 2,104,830,000.00 | 21,864,000.00 | 9,121,916,000.00 | 1,932,448,000.00 | 937,665,000.00 | 0.00 | 14,917,882,000.00 | 900,500,000.00 | 5,769,000.00 | 951,266,000.00 | 5,162,910,000.00 | 47,807,000.00 | 1,265,324,000.00 | 1,728,174,000.00 | 2,121,605,000.00 | 65,716,000.00 | 0.00 | 8,648,392,000.00 | -39,562,000.00 | 8,687,954,000.00 | 83,829,000.00 | 8,795,000.00 | 75,034,000.00 | 8,795,000.00 | 75,034,000.00 |
| 2022-03-31T00:00:00 | annual | 0.00 | 92,600,000.00 | 92,600,000.00 | 5,167,271,000.00 | 5,428,153,000.00 | 10,362,078,000.00 | 15,747,003,000.00 | 4,533,147,000.00 | 10,362,078,000.00 | 44,761,000.00 | 10,363,611,000.00 | 11,748,599,000.00 | 10,363,014,000.00 | -597,000.00 | 10,363,611,000.00 | 9,437,600,000.00 | 8,787,496,000.00 | 36,198,000.00 | 926,000,000.00 | 926,000,000.00 | 11,716,570,000.00 | 2,315,989,000.00 | -3,000.00 | 0.00 | 93,865,000.00 | 1,699,000.00 | 724,308,000.00 | 1,403,782,000.00 | 18,794,000.00 | 1,384,988,000.00 | 92,335,000.00 | 9,400,581,000.00 | -435,000,000.00 | 4,024,371,000.00 | 25,967,000.00 | 3,998,404,000.00 | 37,135,000.00 | 37,100,000.00 | 5,339,075,000.00 | 615,706,000.00 | 7,181,000.00 | 29,446,000.00 | 4,686,742,000.00 | 22,079,584,000.00 | 8,145,854,000.00 | 284,400,000.00 | 284,354,000.00 | 194,804,000.00 | 194,804,000.00 | 1,533,000.00 | 1,533,000.00 | 7,949,517,000.00 | -4,790,636,000.00 | 12,740,153,000.00 | 1,051,723,000.00 | 40,864,000.00 | 8,792,291,000.00 | 1,920,680,000.00 | 934,595,000.00 | 0.00 | 13,933,728,000.00 | -1,000.00 | 7,181,000.00 | 704,339,000.00 | 5,259,424,000.00 | 56,198,000.00 | 1,255,428,000.00 | 1,625,266,000.00 | 2,322,532,000.00 | 247,644,000.00 | 0.00 | 7,499,020,000.00 | -42,784,000.00 | 7,541,804,000.00 | 216,121,000.00 | 126,400,000.00 | 216,121,000.00 | 12,842,000.00 | 203,279,000.00 |
| 2021-03-31T00:00:00 | annual | 0.00 | 93,200,000.00 | 93,200,000.00 | 3,355,683,000.00 | 3,507,579,000.00 | 9,131,694,000.00 | 12,578,058,000.00 | 4,614,407,000.00 | 9,131,694,000.00 | 63,767,000.00 | 9,134,246,000.00 | 10,609,835,000.00 | 9,134,078,000.00 | -168,000.00 | 9,134,246,000.00 | 0.00 | 7,537,991,000.00 | 30,198,000.00 | 932,000,000.00 | 932,000,000.00 | 8,526,058,000.00 | 2,572,499,000.00 | 7,960,000.00 | 0.00 | 63,395,000.00 | 1,699,000.00 | 771,342,000.00 | 1,511,389,000.00 | 35,800,000.00 | 1,475,589,000.00 | 216,714,000.00 | 5,953,559,000.00 | -396,083,000.00 | 1,996,190,000.00 | 27,967,000.00 | 1,968,223,000.00 | 27,957,000.00 | 28,000,000.00 | 3,929,412,000.00 | 484,102,000.00 | 9,658,000.00 | 135,970,000.00 | 3,299,682,000.00 | 17,660,136,000.00 | 7,092,170,000.00 | 72,600,000.00 | 72,606,000.00 | 173,007,000.00 | 173,007,000.00 | 2,552,000.00 | 2,552,000.00 | 6,916,611,000.00 | -4,322,466,000.00 | 11,239,077,000.00 | 265,178,000.00 | 58,942,000.00 | 8,382,939,000.00 | 1,882,208,000.00 | 649,810,000.00 | 0.00 | 10,567,966,000.00 | 640,700,000.00 | 9,658,000.00 | 535,835,000.00 | 4,150,027,000.00 | 37,074,000.00 | 894,893,000.00 | 1,124,231,000.00 | 2,093,829,000.00 | 232,022,000.00 | 0.00 | 5,552,295,000.00 | -34,879,000.00 | 5,587,174,000.00 | 88,129,000.00 | 127,200,000.00 | 88,129,000.00 | 29,108,000.00 | 59,021,000.00 |
| 2020-03-31T00:00:00 | annual | 1,128,400.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 68,725,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29,014,000.00 | 0.00 |
NSE: AARTIDRUGS Cash Flow Data In (Cr)
| date | period_type | Free Cash Flow | Repurchase Of Capital Stock | Repayment Of Debt | Issuance Of Debt | Issuance Of Capital Stock | Capital Expenditure | End Cash Position | Other Cash Adjustment Outside Changein Cash | Beginning Cash Position | Changes In Cash | Financing Cash Flow | Net Other Financing Charges | Interest Paid Cff | Cash Dividends Paid | Common Stock Dividend Paid | Net Common Stock Issuance | Common Stock Payments | Common Stock Issuance | Net Issuance Payments Of Debt | Net Short Term Debt Issuance | Net Long Term Debt Issuance | Long Term Debt Payments | Long Term Debt Issuance | Investing Cash Flow | Net Other Investing Changes | Interest Received Cfi | Dividends Received Cfi | Net Investment Purchase And Sale | Sale Of Investment | Purchase Of Investment | Net PPE Purchase And Sale | Sale Of PPE | Purchase Of PPE | Operating Cash Flow | Taxes Refund Paid | Change In Working Capital | Change In Payable | Change In Inventory | Change In Receivables | Other Non Cash Items | Provisionand Write Offof Assets | Depreciation And Amortization | Amortization Cash Flow | Depreciation | Gain Loss On Investment Securities | Net Foreign Currency Exchange Gain Loss | Gain Loss On Sale Of PPE | Net Income From Continuing Operations |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31T00:00:00 | annual | 1,325,887,000.00 | -598,500,000.00 | -459,360,000.00 | 1,481,850,000.00 | 0.00 | -2,263,345,000.00 | 67,427,000.00 | 0.00 | 75,034,000.00 | -7,607,000.00 | -1,360,331,000.00 | -133,230,000.00 | -313,083,000.00 | -92,673,000.00 | 0.00 | -598,500,000.00 | -598,500,000.00 | 0.00 | -222,845,000.00 | -1,245,335,000.00 | 1,022,490,000.00 | -459,360,000.00 | 1,481,850,000.00 | -2,236,508,000.00 | -1,000.00 | 24,955,000.00 | 11,000.00 | 0.00 | 0.00 | 0.00 | -2,261,473,000.00 | 1,872,000.00 | -2,263,345,000.00 | 3,589,232,000.00 | -623,995,000.00 | 1,027,849,000.00 | -925,312,000.00 | 342,458,000.00 | 1,610,703,000.00 | 310,195,000.00 | 18,958,000.00 | 514,473,000.00 | 3,989,000.00 | 510,484,000.00 | 1,823,000.00 | -18,266,000.00 | 0.00 | 2,355,278,000.00 |
| 2023-03-31T00:00:00 | annual | -314,966,000.00 | 0.00 | -558,611,000.00 | 1,158,382,000.00 | 7,556,000.00 | -1,648,178,000.00 | 75,034,000.00 | 0.00 | 216,120,000.00 | -141,086,000.00 | 165,422,000.00 | 1,000.00 | -361,863,000.00 | -94,013,000.00 | 0.00 | 7,556,000.00 | 0.00 | 7,556,000.00 | 613,741,000.00 | 13,970,000.00 | 599,771,000.00 | -558,611,000.00 | 1,158,382,000.00 | -1,639,720,000.00 | 1,000.00 | 6,992,000.00 | 11,000.00 | 0.00 | 0.00 | 0.00 | -1,646,724,000.00 | 1,454,000.00 | -1,648,178,000.00 | 1,333,212,000.00 | -596,748,000.00 | -1,163,371,000.00 | -277,366,000.00 | 58,218,000.00 | -944,223,000.00 | 354,871,000.00 | 7,594,000.00 | 503,241,000.00 | 648,000.00 | 502,593,000.00 | -1,123,000.00 | -13,074,000.00 | -1,112,000.00 | 2,241,821,000.00 |
| 2022-03-31T00:00:00 | annual | -815,609,000.00 | -600,000,000.00 | -68,700,000.00 | 2,028,200,000.00 | 0.00 | -1,519,749,000.00 | 216,120,000.00 | -1,000.00 | 88,129,000.00 | 127,992,000.00 | 920,251,000.00 | -138,377,000.00 | -205,785,000.00 | -95,077,000.00 | 0.00 | -600,000,000.00 | -600,000,000.00 | 0.00 | 1,959,490,000.00 | 0.00 | 1,959,490,000.00 | -68,700,000.00 | 2,028,200,000.00 | -1,496,399,000.00 | -100,000.00 | 7,169,000.00 | 15,981,000.00 | 0.00 | 0.00 | 0.00 | -1,519,549,000.00 | 200,000.00 | -1,519,749,000.00 | 704,140,000.00 | -833,767,000.00 | -1,873,513,000.00 | 1,171,459,000.00 | -1,106,302,000.00 | -1,938,670,000.00 | 198,616,000.00 | 16,865,000.00 | 500,489,000.00 | 407,000.00 | 500,082,000.00 | -15,981,000.00 | 12,052,000.00 | -169,000.00 | 2,699,551,000.00 |
| 2021-03-31T00:00:00 | annual | 667,190,000.00 | 0.00 | -349,700,000.00 | 0.00 | 0.00 | -882,313,000.00 | 88,130,000.00 | 0.00 | 67,713,000.00 | 20,417,000.00 | -811,290,000.00 | 100,000.00 | -229,571,000.00 | -232,052,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | -349,667,000.00 | 0.00 | -349,667,000.00 | -349,700,000.00 | 0.00 | -717,796,000.00 | -1,000.00 | 25,958,000.00 | 29,700,000.00 | 0.00 | 0.00 | 0.00 | -773,453,000.00 | 108,860,000.00 | -882,313,000.00 | 1,549,503,000.00 | -966,753,000.00 | -1,859,921,000.00 | -313,880,000.00 | -891,849,000.00 | -654,192,000.00 | 203,613,000.00 | 8,466,000.00 | 498,835,000.00 | 11,755,000.00 | 487,080,000.00 | -62,368,000.00 | 7,071,000.00 | 0.00 | 3,690,139,000.00 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 100,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -70,300,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 26,195,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -44,557,000.00 | 0.00 |
NSE: AARTIDRUGS Income Statement Data In (Cr)
| date | period_type | Tax Effect Of Unusual Items | Tax Rate For Calcs | Normalized EBITDA | Total Unusual Items | Total Unusual Items Excluding Goodwill | Net Income From Continuing Operation Net Minority Interest | Reconciled Depreciation | Reconciled Cost Of Revenue | EBITDA | EBIT | Net Interest Income | Interest Expense | Interest Income | Normalized Income | Net Income From Continuing And Discontinued Operation | Total Expenses | Rent Expense Supplemental | Diluted Average Shares | Basic Average Shares | Diluted EPS | Basic EPS | Diluted NI Availto Com Stockholders | Net Income Common Stockholders | Otherunder Preferred Stock Dividend | Net Income | Minority Interests | Net Income Including Noncontrolling Interests | Net Income Continuous Operations | Tax Provision | Pretax Income | Other Non Operating Income Expenses | Special Income Charges | Other Special Charges | Write Off | Net Non Operating Interest Income Expense | Total Other Finance Cost | Interest Expense Non Operating | Interest Income Non Operating | Operating Income | Operating Expense | Other Operating Expenses | Depreciation And Amortization In Income Statement | Amortization | Depreciation Income Statement | Selling General And Administration | Selling And Marketing Expense | General And Administrative Expense | Gross Profit | Cost Of Revenue | Total Revenue | Operating Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31T00:00:00 | annual | -0.64 | 0.00 | 322.86 | -2.37 | -2.37 | 171.42 | 51.45 | 2,024.01 | 320.49 | 269.04 | -35.39 | 33.52 | 2.50 | 173.15 | 171.42 | 2,231.17 | 0.06 | 9.19 | 9.19 | 0.00 | 0.00 | 171.42 | 171.42 | 0.00 | 171.42 | -0.17 | 171.59 | 171.59 | 63.94 | 235.53 | -4.41 | -2.37 | 0.18 | 2.19 | -35.39 | 4.37 | 33.52 | 2.50 | 277.70 | 207.16 | 0.59 | 51.45 | 0.40 | 51.05 | 71.87 | 57.69 | 14.18 | 484.87 | 2,024.01 | 2,508.87 | 2,508.87 |
| 2023-03-31T00:00:00 | annual | -0.39 | 0.00 | 309.33 | -1.53 | -1.53 | 166.31 | 50.32 | 2,222.60 | 307.80 | 257.48 | -36.44 | 33.29 | 0.70 | 167.44 | 166.31 | 2,439.22 | 0.06 | 9.26 | 9.26 | 0.00 | 0.00 | 166.31 | 166.31 | 0.00 | 166.31 | -0.05 | 166.36 | 166.36 | 57.82 | 224.18 | -4.20 | -1.53 | 0.00 | 1.53 | -36.44 | 3.84 | 33.29 | 0.70 | 266.35 | 216.62 | 0.62 | 50.32 | 0.06 | 50.26 | 83.59 | 69.81 | 13.79 | 482.97 | 2,222.60 | 2,705.57 | 2,705.57 |
| 2022-03-31T00:00:00 | annual | -0.41 | 0.00 | 342.44 | -1.69 | -1.69 | 205.04 | 50.05 | 1,984.98 | 340.75 | 290.70 | -23.19 | 20.75 | 0.72 | 206.32 | 205.04 | 2,190.85 | 0.06 | 9.26 | 9.26 | 0.00 | 0.00 | 205.04 | 205.04 | 0.00 | 205.04 | 0.04 | 205.00 | 205.00 | 64.96 | 269.96 | -4.56 | -1.69 | 0.00 | 1.69 | -23.19 | 3.16 | 20.75 | 0.72 | 297.80 | 205.87 | 0.32 | 50.05 | 0.04 | 50.01 | 81.59 | 68.36 | 13.23 | 503.66 | 1,984.98 | 2,488.65 | 2,488.65 |
| 2021-03-31T00:00:00 | annual | -0.15 | 0.00 | 442.48 | -0.62 | -0.62 | 280.41 | 49.88 | 1,554.47 | 441.85 | 391.97 | -23.63 | 22.96 | 2.60 | 280.89 | 280.41 | 1,758.89 | 0.06 | 9.32 | 9.32 | 0.00 | 0.00 | 280.41 | 280.41 | 0.00 | 280.41 | 0.01 | 280.40 | 280.40 | 88.62 | 369.01 | -3.64 | -0.62 | -3.27 | 3.89 | -23.63 | 3.27 | 22.96 | 2.60 | 395.89 | 204.42 | 0.39 | 49.88 | 1.18 | 48.71 | 74.46 | 65.02 | 9.44 | 600.31 | 1,554.47 | 2,154.78 | 2,154.78 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4.47 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
FII & DII Data (In Cr)
| Date | FII Gross Purchase | FII Gross Sales | FII Net Purchase / Sales | DII Gross Purchase | DII Gross Sales | DII Net Purchase / Sales |
|---|---|---|---|---|---|---|
| 2025-02-03 | 12,505.92 | 16,464.29 | -3,958.37 | 19,319.48 | 16,611.25 | 2,708.23 |
| 2025-01-30 | 10,513.63 | 15,096.58 | -4,582.95 | 13,934.35 | 11,768.46 | 2,165.89 |
| 2025-01-29 | 7,644.40 | 10,230.83 | -2,586.43 | 12,871.38 | 11,078.67 | 1,792.71 |
| 2025-01-27 | 9,488.57 | 14,504.03 | -5,015.46 | 16,503.43 | 9,861.28 | 6,642.15 |
| 2025-01-24 | 11,230.47 | 13,988.96 | -2,758.49 | 12,835.41 | 10,433.10 | 2,402.31 |
| 2025-01-23 | 13,316.55 | 18,779.07 | -5,462.52 | 14,412.73 | 10,700.18 | 3,712.55 |
| 2025-01-22 | 12,936.64 | 16,962.89 | -4,026.25 | 15,437.18 | 11,796.96 | 3,640.22 |
Piotroski F-Score
3/9
0
1
2
3
4
5
6
7
8
9
Key Metrics
EPS
16.57
P/E
25.540134
P/B
3.0237646
Dividend Yield
0.23%
Market Cap
3,862.55 Cr.
Face Value
139.958
Book Value
139.958
ROE
6.4%
EBITDA Growth
286.78 Cr.
Debt/Equity
46.181
Short Term
Subscribe to unlock this feature
Medium Term
Subscribe to unlock this feature
Long Term
Subscribe to unlock this feature
Yearly Stock Performance Heatmap
Latest Updates
Ashoka Buildcon Arm Signs Rs 1,391 Crore Pact With NHAI
Ashoka Buildcon Ltd. announced on Monday, via an exchange filing, that its wholly owned subsidiary, Ashoka Bowaichandi Guskara Road Pvt Ltd., has exec...
Budget 2025: Rahul Bajoria On Addressing Income Growth And Consumption Trends
"However, discretionary, high-value consumption is taking a step back due to income growth settling at high single digits." Over the past fe...
FPIs Stay Net Sellers, Sell Stocks Worth Rs 2,575 Crore
Foreign portfolio investors stayed net sellers for the second straight session on Monday and sold stocks worth approximately Rs 2,575.1 crore, accordi...
Budget 2025: AMFI Seeks Tax Policy Reforms To Drive Mutual Fund Investments In 15-Point Proposal
The Association of Mutual Funds of India on Monday released a 15-point proposal for Union Budget 2025-26 requesting changes in tax policies that are i...
Apple iPhone SE 4: Price To Features, 11 Things You Need To Know
iPhone 16e (Not iPhone SE 4): If recent reports are to be believed, Apple may discontinue the SE label and rename iPhone SE 4 as iPhone 16e. Most Affo...
Rupee Closed Weaker Against The US Dollar
The rupee weakened by five paise to close at 85.83 against the US dollar. The Indian rupee had declined to a fresh low against the US dollar during th...
Table Space Founder Amit Banerji Dies Of Heart Attack At Age Of 45
Amit Banerji, the founder, chairman and chief executive officer of managed workspace provider Table Space, died after suffering from a heart attack, r...
War Fatigue, Economic Breakdown Or Pro-West? Why Syria's Al-Sharaa Is Seen Soft On Israel
The strategic positions have been used by Israeli forces to carry out hundreds of strikes to destroy Syria's military infrastructure. In 2011, be...
Popular Questions
What is the Market Cap of aartidrugs?
The market capitalization of Aarti Drugs Limited is ₹3,863 Cr as of 05 Feb 2025.
What are the PE and PB ratios of Aarti Drugs Limited?
The PE and PB ratios of Aarti Drugs Limited are Not Available and 3.0237646 respectively as of 05 Feb 2025.
What is the 52 Week High of Aarti Drugs Limited?
The 52-week high of Aarti Drugs Limited is ₹635 as of 05 Feb 2025.
What is the 52 Week Low of Aarti Drugs Limited?
The 52-week low of Aarti Drugs Limited is ₹419.55 as of 05 Feb 2025.
What are the earnings per share (EPS) for Aarti Drugs Limited?
The Earnings Per Share (EPS) of Aarti Drugs Limited is ₹16.57 as per the most recent quarterly results available on Fincept.
What is the ROE (Return on Equity) of Aarti Drugs Limited?
The Return on Equity (ROE) of Aarti Drugs Limited is 6.4% as per the most recent financial year data. Explore more on Fincept.